Future trials in patients with IDH‐mutant gliomas of different grades of malignancy (2–4) should investigate the efficacy of IDH inhibitors on pharmacoresistant seizures and validate the additional value of PET monitoring with amino acid tracers in evaluating both tumor and seizure response over the entire disease trajectory (before and after surgery and following chemotherapy and targeted agents). This evidence concerns the gene IDH1 and neoplasm.